Editas Medicine Inc (NAS:EDIT)
$ 1.199 -0.011 (-0.91%) Market Cap: 99.88 Mil Enterprise Value: -126.72 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 46/100

Editas Medicine Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2019 / 03:15PM GMT
Release Date Price: $23.94 (-1.16%)
Gena Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. My name is Gena Wang. I'm the [SME-cap] biotech analyst at Barclays. It is my great pleasure to introduce our next speakers, Charlie Albright, Chief Scientific Officer from Editas. Also together with us, we have Cindy Collins, Interim CEO with us for Q&A session.

Charles Albright
Editas Medicine, Inc. - Chief Scientific Officer

Thank you, Gena. It's a pleasure to be here. Developing innovative medicines with a new technology is an area with great promise. It's also an area with some risk. And for that reason, I'll be making forward-looking statements, and I encourage you to read the slide at your convenience.

Our mission at Editas is to take the incredible power of CRISPR gene editing and turn it into transformational medicines. I want to update you today on where we are on that -- on accomplishing that mission, and I want to start by the progress we've made in 2018.

Certainly, one of the largest things we did last year was to get filed and have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot